NCT04454892 Natural History and Clinical Features of Amyotrophic Lateral Sclerosis (ALS)
| NCT ID | NCT04454892 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University Third Hospital |
| Condition | Amyotrophic Lateral Sclerosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2019-11-01 |
| Primary Completion | 2030-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2019-11-01 with a primary completion date of 2030-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
1. Describe the distribution of ALS in mainland China, to explore the differences in the number of ALS in different times, regions and populations in order to further explore the causes affecting the distribution of ALS; 2. To investigate the cause of ALS in mainland China in the crowd disease development process and the corresponding characteristics change ; 3. To explore the effect of prognosis of ALS;
Eligibility Criteria
Inclusion Criteria: \- Patients were diagnosed with ALS recruited from all participant clinical centers.The diagnosis of ALS was made using the revised El Escorial criteria for definite, probable, lab-supported, and possible. Exclusion Criteria: * Decline to follow-up.
Contact & Investigator
Dongsheng Fan, MD.PHD
PRINCIPAL INVESTIGATOR
Peking University Third Hospital
Frequently Asked Questions
Who can join the NCT04454892 clinical trial?
This trial is open to participants of all sexes, studying Amyotrophic Lateral Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04454892 currently recruiting?
Yes, NCT04454892 is actively recruiting participants. Contact the research team at tanglu@bjmu.edu.cn for enrollment information.
Where is the NCT04454892 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT04454892 clinical trial?
NCT04454892 is sponsored by Peking University Third Hospital. The principal investigator is Dongsheng Fan, MD.PHD at Peking University Third Hospital. The trial plans to enroll 3,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.